Nuvation Bio vs UroGen Pharma
NUVB and URGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NUVB and URGN compare
Nuvation Bio and UroGen Pharma are about the same size, with market caps of $1.4B and $1.5B.
Nuvation Bio grew revenue faster over the last twelve months (1084% versus 100% for UroGen Pharma).
UroGen Pharma keeps more of each dollar of sales as profit, with a net margin of −51.7% compared with −88.2% at Nuvation Bio.
UroGen Pharma scores higher on the StockData Score (6 against 4 for Nuvation Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NUVB | URGN |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | $1.5B |
| Share price | $3.90 | $29.87 |
| Change, 1 year | −19.8% | 25.7% |
| Change, 5 years | −52.3% | 146% |
| Beta (5Y) | 1.77 | 2.73 |
| Employees | 298 | 291 |
| StockData Score | ||
| Total score | 4 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.1× | 7.7× (better) |
| P/B | 5.4× | – |
| FCF yield | – | −10.9% |
| Fair value | $1.89 | – |
| Margin of safety | −107% | – |
| Growth | ||
| Revenue growth (TTM) | 1084% (better) | 100% |
| Revenue growth, 5Y average | – | 56.2% |
| Profitability | ||
| Gross margin | – | 90.8% |
| Operating margin | −81.0% | −35.3% (better) |
| Net margin | −88.2% | −51.7% (better) |
| FCF margin | – | −84.3% |
| Return on equity | −47.8% | – |
| Financial health | ||
| Debt / equity | 0.02 | – |
| Interest coverage | −5.4× | – |
| Current ratio | 8.37 (better) | 3.80 |
| Altman Z-score | 0.12 (better) | −2.55 |
| Piotroski F-score | 4 (better) | 0 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 66.5% | 86.8% |
| Held by insiders | 24.6% | 5.6% |
| Insider net buying, 12 months | −$4.5M (better) | −$4.5M |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 23.4% | 11.1% |
Go deeper
- NUVB stock overview
- NUVB income statement
- NUVB valuation and score
- URGN stock overview
- URGN income statement
- URGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.